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TransplantatABSTRACT
Mucormycosis is an uncommonly encountered fungal infection in solid organ trans-
plantation. The infection is severe and often results in a fatal outcome. The most common
presentations are rhino-sino-orbital and pulmonary disease. We describe a rare case of
gastric mucormycosis in a patient with a combined liver-kidney transplant affected by
glycogen storage disease type Ia.
A 42-year-old female patient presented with gastric pain and melena 26 days after trans-
plantation. Evaluation with upper endoscopy showed two bleeding gastric ulcers. Histo-
logical examination of gastric specimens revealed fungal hyphae with evidence of
Mucormycetes at subsequent molecular analysis. Immunosuppressive therapy was reduced
and antifungal therapy consisting of liposomal amphotericin B and posaconazole was
promptly introduced. Gastrointestinal side effects of posaconazole and acute T-cell
rejection of renal graft complicated management of the case. A prolonged course of daily
injections of amphotericin B together with a slight increase of immunosuppression favored
successful treatment of mucormycosis as well as of graft rejection. At 2-year follow-up, the
woman was found to have maintained normal renal and liver function. We conclude that
judicious personalization of antimicrobial and antirejection therapy should be considered
to resolve every life-threatening case of mucormycosis in solid organ transplantation.*Address correspondence to Gaetano Alfano, MD, University
Hospital of Modena, Via del Pozzo, 71, 41124, Modena, Italy.
E-mail: alfano.gaetano.md@gmail.comMUCORMYCOSIS, previously termed zygomycosis,indicates an uncommon but serious opportunistic
infection caused by fungi [1]. The termmucormycosis derives
fromMucormycete, a distinctive group of ubiquitous mycetes
growing principally on decaying vegetation and organic ma-
terials [2]. The most common genera are Rhizopus, Mucor,
and Abside [3]. Mucormycetes infect principally immuno-
compromised subjects with hematologic malignancies [4] and
diabetes mellitus [5]. However, several cases have been re-
ported in immunocompetent subjects with multiple trauma
[6] or after therapy with deferoxamine [7].
Mucormycosis is a rare complication of solid organ
transplantation (SOT) with an incidence of 0.07% at 1
year after transplantation [8,9]. Clinical manifestations can
be nonspecific; therefore, diagnosis is often challenging.
Sinus-rhinocerebral and lung disease are the mostlished by Elsevier Inc.
enue, New York, NY 10169
ion Proceedings, 50, 905e909 (2018)common clinical presentations of mucormycosis [10]. Data
regarding treatment are scarce and limited by lack of
randomized trials. Generally, therapeutic options rely on
few antifungal agents with high toxic profile and with
potential for drug interactions with immunosuppressive
drugs [11]. Despite appropriate antifungal treatment and
aggressive surgical intervention, mortality is particularly
high compared to the other common infectious diseases
such as candidiasis and aspergillosis; it ranges from 50% to
100% depending on the localization of the disease
[12e14].0041-1345/18
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906 ALFANO, FONTANA, FRANCESCA ET ALWe describe a complex case of enteric mucormycosis in a
subject affected by inherited metabolic disorder (ie,
glycogen storage disease type Ia [GSD Ia]) who underwent
combined liver-kidney transplantation for end-stage liver
and kidney disease. We report the successful therapeutic
strategy of this life-threatening infection that consisted in a
delicate and challenging balance between administration of
antifungal therapy and reduction of antirejection drugs.CASE DESCRIPTION
A 42-year-old female patient reported abdominal pain and dark
stool after a combined liver-kidney transplantation.
In September 2015, the woman affected by GSD Ia had been
admitted for combined liver-kidney transplantation from deceased
donator for chronic liver failure with a Model for End-stage Liver
Disease score of 20 and end-stage renal disease on hemodialysis.
Liver failure occurred as a consequence of the GSD I as confirmed
by histological investigation, whereas the same metabolic etiology of
renal disease was only presumptive because renal biopsy was never
performed. Immunosuppression included intravenous methylpred-
nisolone induction followed by oral tacrolimus, steroids, and
mycophenolate mofetil (MMF). Nystatin and valganciclovir were
used for oropharyngeal candidiasis and cytomegalovirus (CMV)
prophylaxis, respectively. Early postoperative course was compli-
cated by internal bleeding from tissue the surrounding transplanted
kidney that was promptly treated by laparoscopic surgery, and by a
biopsy-proven acute tubular necrosis (ATN) consequent to hem-
orrhagic shock. Kidney allograft function improved slowly and the
serum creatinine reached a value of 1.5 mg/dL after 3 weeks. On the
postoperative day (POD) 26 after transplantation, she was promptly
evaluated for upper gastrointestinal bleeding as soon as she re-
ported gastric pain and melena. Physical examination revealed the
presence of peristaltic bowel sounds and epigastric tenderness on
deep palpation of abdomen; rectal examination confirmed the
presence of dark “tarry” feces. Upper gastrointestinal endoscopy
showed two ulcers on the posterior wall of the gastric body without
signs of active bleeding (Forrest classification III). The proximal
and distal ulcer had a diameter of 2  2 cm and 3  4 cm,
respectively; both of them had a grayish base covered by necrotic
material, surrounded by hyperemic mucosa. Biopsy specimens of
gastric ulcers displayed the presence of several fungal hyphae in a
contest of active ulcerative chronic gastritis. Fungi stained withFig 1. Ulcerative gastritis with fungal forms invasion (arrows) with r
staining with (A) periodic acideSchiff (original magnification
magnification 200).periodic acid-Schiff (Fig 1A) showed a relatively faint and
nonuniform staining with Grocott methenamine-silver (Fig 1B).
The hyphae, often forming helical twists, have a relatively broad
width with very rare septa. Helicobacter pylori and CMV were not
detected on biopsy specimens. The morphology and staining char-
acteristics strongly suggested the presence of Mucormycetes. Mo-
lecular analysis of gastric tissue using polymerase chain reaction
detected Mucormycetes of the genus Rhizopus. Brain and lung
computed tomography scans were performed to exclude metastatic
spread of infection; both results were negative.
Management of mucormycosis was based on a prompt start of
appropriate antifungal therapy and a reversal of underlying predis-
posing factors for infection, such as immunosuppressive therapy. On
POD 42, she started induction antifungal therapy with intravenous
liposomal amphotericin B at a dose of 5 mg/kg per day; after 5 days,
this drug was switched to oral posaconazole at a dose of 100 mg 3
times a day (target trough level> 2 mg/mL). After steroids andMMF
withdrawal, immunosuppressive therapy was maintained with
tacrolimus (target trough level of 4 to 7 ng/mL). We planned a pro-
longed course of antifungal treatment lasting for at least 6 months
along with a surveillance endoscopy every 2months. At POD 50 after
transplantation, she was discharged in good general condition
without gastrointestinal symptoms. In December 2016, after 1 month
from discharge, the woman was again admitted to the hospital with
severe gastrointestinal symptoms including vomiting and anorexia
that were attributed to side effects of posaconazole administration.
Posaconazole withdrawal and restarting of liposomal amphotericin B
completely resolved these symptoms. The case was further compli-
cated by CMV reactivation with tissue invasive disease of the oral
mucosa that required specific treatment with valganciclovir. At
discharge, posaconazole was reintroduced at a reduced dose of 100
mg twice daily with a target trough level of 1 to 2mg/mL.Nevertheless,
gastrointestinal side effects were so debilitating that the drug was
definitively stopped and once again she was started on liposomal
amphotericin B. After 1 month from her second discharge, renal
function deteriorated progressively requiring admission. The serum
creatinine level rose from her baseline values of 1.6 mg/dL to
3.2 mg/dL; a trial of normal saline rehydration did not improve renal
function. The patient underwent allograft biopsy which was compli-
cated by internal bleeding needing endovascular embolization of the
polar inferior artery. Histologic examination showed acute T-cell
rejection (Banff classification IA) with ATN. The rejection was
treated by adding MMF 500 mg twice daily to tacrolimus; steroids
were intentionally excluded from treatment. Recovery of renalare septations, broad and irregular width hyphae (10 to 20 mm),
200) and with (B) Grocott methenamine silver (original
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2 mg/dL. At discharge, she continued daily intravenous therapy with
liposomal amphotericin B as an outpatient. The endoscopic evalua-
tion performed 6months after the initial presentation showedhealing
of the previous two ulcers. Histological and molecular analyses were
negative for Mucormycetes. Antifungal therapy was stopped after
6 months for successful resolution of infection. Lastly, in view of a
progressive increment of blood and urine BK viral load, immuno-
suppressive therapy was further reduced. The dose of tacrolimus was
adjusted to obtain a target trough level of 4 to 7 ng/mLand the dose of
MMF was halved (250 mg twice daily). These changes led to a
complete resolution of BK virus reactivation over the next 6 months.
The woman remained well after 2 years from combined liver-kidney
transplantation; she had a stable renal function with a serum creati-
nine level of 2 mg/dL (estimated glomerular filtration rate of
29 mL/min) and normal liver function tests.
DISCUSSION
After, Candida and Aspergillus spp., Mucormycetes repre-
sents an emerging cause of invasive fungal infection [15,16].
Incidence of mucormycosis varies between series: in kidney
transplant recipients it is of 0.05% to 1.2% [17e19] and in
liver recipients it is 0.4% to 1.61% [20,21]. Clinical pre-
sentation is highly heterogeneous, and it can involve a
specific organ or be disseminated. In a review of 116 cases in
SOT, Almyroudis et al [10] found that rhino-orbital-cerebral
was the most common site of fungal infection (31%), fol-
lowed by lung parenchyma (24.1%) and gastrointestinal
tract (11.2%). Regarding gastrointestinal involvement, the
stomach is the most prevalent site of infection followed by
colon, esophagus, and liver. Gastrointestinal mucormycosis
carries a significant morbidity and mortality among trans-
plant recipients because it can lead to bowel perforation and
death [4]. Cases of mucormycosis in combined liver-kidney
transplantation are rarely reported in the literature [22];
to the best of our knowledge, this is the first case of gastric
mucormycosis in a combined liver-kidney transplantation.
Gastric mucormycosis frequently presents with epigastric
pain, melena, and hematemesis; upper gastrointestinal
endoscopy usually shows a solitary or multiple ulcers
mimicking a common peptic ulcer [10]. Unfortunately, this
clinical presentation is nonspecific and tends to cause
diagnostic delay, which in turn increases patient mortality
[23]. Diagnosis of mucormycosis remains challenging and is
based on direct histologic identification of the characteristic
hyphae or on retrieval of the Mucormycetes in culture of
specimens obtained from the site of infection [24]. The tests
commonly used to detect fungal antigens (ie, b-D-glucan
test and Aspergillus galactomannan) are not reliable for
diagnosis of mucormycosis [23,25]. In our case, cooperation
with a skilled pathologist, who identified the characteristic
hyphae from biopsy specimens of gastric ulcers, allowed an
early suspicion of mucormycosis. The disease generally de-
velops on average within 6 months from transplantation
when high burden of immunosuppression increases the risk
of opportunistic infections [10,26]. A prospective, matched
case-controlled study revealed that renal failure, diabetes
mellitus, and prior use of voriconazole and/or caspofunginwere significantly associated with a higher risk of mucor-
mycosis. In addition, liver transplant recipients are more
likely to develop a severe, early infection than other types of
SOT recipients [27]. In line with the literature, in our case
mucormycosis was detected during the second month from
transplantation. Although the patient had an unknown
predisposition to infections before transplantation, she
showed a unique susceptibility to multiple opportunistic
pathogens (Mucormycetes, CMV, and polyomavirus BK).
Likely factors such as the multiple episodes of bleeding,
ATN, and early access in the intensive care unit have
contributed to further enhance her immunosuppression.
Unlike GSD type Ib, type Ia (the inherited metabolic dis-
order of our patient) is not generally associated with an
impaired immune surveillance [28]. However, a certain de-
gree of neutrophil dysfunction has been documented in
some subjects with GSD Ia [29].
Management of Mucormycetes infection is based on the
prompt institution of an appropriate antifungal therapy and
surgery. Current pharmacotherapeutic options include lipid
formulations of amphotericin B or isavuconazole as first-
line therapy and posaconazole as salvage therapy [30].
Amphotericin B deoxycholate, which has been the drug of
choice against Mucormycetes for more than 50 years, is not
currently used due to the high incidence of dose-dependent
nephrotoxicity [31]. Availability of less toxic lipid-based
formulations of amphotericin B has improved the safety
profile of this class of drugs [32,33], and makes them the
first-line therapy for several invasive fungal infections
including mucormycosis [34,35]. The two triazoles, isavu-
conazole and posaconazole, are active agents against
Mucormycetes and are generally used for maintenance
therapy once the clinical stability has been reached
[11,36,37]. To date, guidelines on the duration of treatment
are lacking; generally, treatment tends to be maintained for
as long as necessary to achieve a clinical and radiological
resolution of the infection [35].
Surgical debridement of involved tissues has been asso-
ciated with an improved survival when combined with
medical treatment [12e14,38,39]. In SOT recipients, surgery
is associated with increased survival rates especially for
pulmonary [40] and rhino-orbital-cerebral [41] mucormy-
cosis. However, these studies may have a potential selection
bias given that patients who did not undergo surgical
treatment likely differed in disease severity, organ involve-
ment, and/or comorbidities from those who did undergo
surgery.
In our case, treatment of gastric mucormycosis relied on
antifungal therapy and reduction of immunosuppression.
Medical therapy was based on amphotericin B and pos-
aconazole, but the latter was prematurely discontinued for its
important gastrointestinal side effects. The attempt to
continue posaconazole was based principally on its more
convenient route of administration (oral versus intravenous),
and safer andmore economic profile compared to intravenous
liposomal amphotericin B. Isavuconazole was not considered
because it had not been available in Italy at that time. We
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surgery because institution of early therapy controlled the
disease and resolved the gastrointestinal symptoms progres-
sively.Moreover, surgical debridement could haveexposed the
patient to over-immunosuppression from the stress associated
with the procedure and the risk of a further postoperative
hemorrhage in a subject with bleeding diathesis due to GSD I
[42,43].
In SOT recipients, treatment of life-threatening infections
may be associated with reduction of immunosuppression to
restore host immunological response. We tried to manage
this difficult case with withdrawal of steroid and MMF and
continued monotherapy with tacrolimus, but an episode of
kidney rejection further complicated clinical management of
the infection. In view of a high risk of systemic fungal
dissemination associated with the treatment of graft rejection
[10], we decided to refrain from using conventional therapy
with glucocorticoid, commonly used to treat T cell-mediated
rejection, as advocated by European guidelines for treatment
of mucormycosis [35]. On the other hand, we cautiously
potentiated immunosuppressive therapy with MMF that
maintained renal function stable over time without threat-
ening the successful treatment of mucormycosis.
In conclusion, this report emphasizes the importance of
early diagnosis, effective antifungal therapy, and reduction
of immunosuppressive therapy in the successful manage-
ment of severe cases of mucormycosis in SOT. Furthermore,
the judicious personalization of antimicrobial and antire-
jection therapy should be always considered as an attempt
to solve complex and life-threatening infections in the
pursuit of the goal of survival after transplantation. Well-
designed randomized trials on the treatment of mucormy-
cosis are needed to establish the best treatment of this
serious disease and clarify the role of surgery in relation to
organ involvement and disease severity.REFERENCES
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